CLINICAL TRIAL SUMMARY

MDACC Study No:2006-1089 (clinicaltrials.gov NCT No: NCT00480987)
Title:A Phase I-II Study of Oxaliplatin, Fludarabine, and Cytarabine in Patients with Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes
Principal Investigator:Gautam Borthakur
Treatment Agent:Cytarabine; Fludarabine; Oxaliplatin
Study Status:Terminated
Study Description:The goal of this clinical research study is to find the highest tolerable dose
of oxaliplatin combined with fludarabine plus cytarabine that can be given to
patients with AML or high-risk MDS. Once the highest tolerable dose of
oxaliplatin in this drug combination is found, the next goal of the study will
be to learn the safety and the ability of the drug combination to control the
disease.

Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase I/Phase II
Treatment Agents:Cytarabine
Fludarabine
Oxaliplatin
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:6 days every 4 weeks
Supported By:N/A
Return Visit:every 1-4 weeks
Home Care:Supportive care


Hide details for Study Contact InformationStudy Contact Information

Physician Name:Gautam Borthakur
Dept:Leukemia
For Clinical Trial Enrollment:713-536-1586
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)


Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults